Supernus Pharmaceuticals SUPN Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's business segments — R&D?
- Supernus Pharmaceuticals (SUPN) reported business segments — R&D of $39.44M in Q1 2026.
- How has Supernus Pharmaceuticals's business segments — R&D changed year-over-year?
- Supernus Pharmaceuticals's business segments — R&D increased by 46.5% year-over-year, from $26.93M to $39.44M.
- What is the long-term trend for Supernus Pharmaceuticals's business segments — R&D?
- Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — R&D has grown at a 12.5% compound annual growth rate (CAGR), from $74.55M to $106.24M.
- What does business segments — R&D mean?
- Measures the total investment in discovering and developing new pharmaceutical products or improving existing ones. High levels of R&D spending indicate a commitment to long-term innovation and future growth potential.